O. V. Polikarpova

O. V. Polikarpova

Auto-generated profile, based on publicly available information

O. V. Polikarpova

Moscow City Clinical Hospital No. 52, Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2025 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
AKA. Yu. Kishkina
A. Yu. Kishkina
NSN. A. Shevchenko
N. A. Shevchenko
EMElena Mladova
Elena Mladova
OPO. V. Polikarpova
O. V. Polikarpova
IGI. M. Grashchenko
I. M. Grashchenko
VGV. M. Grabovskiy
V. M. Grabovskiy
Background. The field of medicine that studies the possibility of preserving reproductive function in cancer patients is intensively developing in the world. Many countries are studying this issue by creating their own databases and national guidelines. In Russia, despite the interest in this problem and discussions at many national conferences, there are no national programs, protocols and clinical recommendations. It creates an obstacle to receiving this type of care for cancer patients. In this regard, the creation of an interdisciplinary system on the preservation of reproductive function in cancer patients becomes relevant. Aim. Formation of interdisciplinary relations between oncologists / hematologists, obstetricians-gynecologists and fertility doctors in order to improve the effectiveness of the care provided on fertility preservation in cancer patients. Materials and methods. The study involved oncologists from the S. S. Yudin City Clinical Hospital, Moscow Healthcare Department, obstetricians-gynecologists and hematologists from the City Clinical Hospital No. 52, Moscow Healthcare Department, as well as reproductive health specialists from the Institute of Reproductive Medicine REMEDI. Oncological patients were recruited on the basis of the S. S. Yudin City Clinical Hospital. A standard scope of examination was undertaken and they were offered antitumor treatment within the framework of the tumor board, taking into account the stage of the disease and the morphological type of the tumor. An obstetrician-gynecologist received patients on the basis of the City Clinical Hospital No. 52. An individual card specially designed for this study was filled in for each patient. The card included data on anamnesis, examination and additional examination methods. A reproductive health specialist received patients on the basis of the Institute of Reproductive Medicine REMEDI. The information obtained during the consultations was added into the specially designed cancer fertility register, with a subsequent assessment of each patient’s status. Results. A multidisciplinary team on fertility preservation was formed with a clear routing of cancer patients when referring to appropriate specialists. Since 2023, 42 oncological and hematological patients have been consulted. A unified database on oncofertility was set up.Conclusion. Our study confirms the need to create a multidisciplinary team to address the issues of preserving reproductive function in cancer patients, providing adequate information to patients about the risks of developing premature ovarian failure during treatment, about possible options for preserving fertility, improving the quality of life and the likelihood of childbirth after the completion of antitumor treatment.

11 September 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
AKA. Yu. Kishkina
A. Yu. Kishkina
NSN. A. Shevchenko
N. A. Shevchenko
EMElena Mladova
Elena Mladova
ОPО. V. Polikarpova
О. V. Polikarpova
IGI. M. Grashchenko
I. M. Grashchenko
ВГВ. М. Грабовский
В. М. Грабовский
Background. Over the past few decades, the advancements in antitumor therapy, early diagnosis, and the development of stem cell transplantation techniques have led to a notable increase in the survival rates of oncohematological patients. Although effective chemotherapy has been shown to prolong lifespan, it can also contribute to toxic effects on gland function, which in women can result in impaired fertility and hormonal disorders related to sex hormone production. In order to mitigate or prevent the irreversible complications of antitumor therapy-induced gonadotoxicity, effective and comprehensive strategies that integrate a variety of options for preserving and restoring fertility should be implemented prior to, during, and following the chemotherapy or radiotherapy.Aim. To test in clinical practice the principles of creating a management plan for oncohematological patients of reproductive age prior to starting special treatment.Materials and methods. The study included 34 female patients of reproductive age with morphologically confirmed hematological diseases who underwent examination, treatment, and follow-up observation at the State Budgetary Healthcare Institution, City Clinical Hospital No. 52 of the Moscow Healthcare Department. All patients were referred for consultation with an obstetrician-gynecologist to evaluate their hormonal status and reproductive potential. Additionally, a multidisciplinary team, including a reproductive health specialist from REMEDI Institute of Reproductive Medicine LLC, assessed ovarian reserve and selected appropriate fertility preservation technique. A comprehensive review and discussion of all clinical cases was conducted within the framework of a multidisciplinary team, leading to a determination of the feasibility of fertility preservation.Results. The material for fertility preservation was collected in 82 % of the patients. Hodgkin’s lymphoma was the most common malignancy (76 %). The methods employed for material collection included transvaginal follicle puncture following controlled ovarian stimulation in 89 % of cases and laparoscopy with ovarian resection / ovariectomy followed by cryopreservation of ovarian tissue in 11 % of cases. The fertility preservation methods included oocyte cryopreservation in 71 % of cases, embryo cryopreservation in 11 % of cases, ovarian tissue cryopreservation in 11 % of cases, and both oocyte and embryo cryopreservation in the remaining 7 % of cases. No complications were reported following assisted reproductive technology procedures.Conclusion. Given the importance of reproductive potential and overall survival in the context of oncohematological diseases, reproductive specialists should prioritize selecting a fertility preservation method before initiating specialized treatment in all patients of reproductive age. The opportunity to procreate constitutes a pivotal component of quality of life for this particular patient population.